Affinity Asset Advisors’s Ocular Therapeutix OCUL Stock Holding History

Affinity Asset Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-239,000	Closed	-$2.79M	–	112
2025 Q3	$2.79M	Buy	+239,000	New	+$2.86M	0.24%	67
2021 Q4	–	Sell	-750,000	Closed	-$7.5M	–	68
2021 Q3	$7.5M	Buy	750,000 +500,000	+200%	+$5.62M	1.89%	10
2021 Q2	$3.54M	Buy	250,000 +22,500	+10%	+$342K	1.27%	20
2021 Q1	$3.73M	Buy	227,500 +7,500	+3%	+$144K	1.27%	19
2020 Q4	$4.55M	Buy	+220,000	New	+$3.27M	2.41%	9

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Affinity Asset Advisors's OCUL Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 239,000 shares — an estimated $2.79M sold.

Affinity Asset Advisors first reported a position in OCUL in Q4 2020 and held it in 5 quarters. The position peaked at $7.5M in Q3 2021. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

Affinity Asset Advisors reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
Affinity Asset Advisors sold 239,000 Ocular Therapeutix shares in Q4 2025, an estimated $2.79M.
Affinity Asset Advisors first reported a position in Ocular Therapeutix in Q4 2020 and held it in 5 quarters.
Affinity Asset Advisors's Ocular Therapeutix position peaked at $7.5M in Q3 2021.
249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.